Extravascular ICD Pilot Study (EV ICD)

The proposed study is designed to characterize the safety and efficacy of a new extravascular implantable cardioverter defibrillator (ICD) system in humans.

Study Overview

• Status: Completed
• Conditions: Tachycardia; Ventricular Arrythmia
• Intervention / Treatment: Device: Defibrillation using the Extravascular ICD

Detailed Description

The study will recruit male and female adult subjects that meet all of the inclusion criteria and none of the exclusion criteria. All subjects will be indicated to receive an ICD.

The EV ICD system will be implanted and the subjects will be followed for at least 3 months following implantation of the system.

Subjects will be exited after follow-up is completed.

• Study Type: Interventional
• Enrollment (Actual): 26
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Australia
  • Brisbane, Australia
    • The Prince Charles Hospital
  • Clayton, Australia
    • MonashHeart
  • Heidelberg, Australia
    • Austin Health
• New Zealand
  • Christchurch, New Zealand
    • Christchurch Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient has a Class I or IIa indication for implantation of an ICD according to the ACC/AHA/HRS Guidelines[1]
2. Patient is willing and able to sign and date the Informed Consent Form.
3. Patient is at least 18 years of age and meets age requirements per local law
4. Patient is geographically stable and willing and able to comply with the study procedures and visits for the duration of the follow-up

[1] Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias

-

Exclusion Criteria:

1. Patient has indications for bradycardia pacing [1] or Cardiac Resynchronization Therapy (CRT) [2] (Class I, IIa, or IIb indication)
2. Patient has an existing or had a prior pacemaker, ICD, or CRT device implant or leads

3. Patient has anatomical abnormality that significantly increases implant risk[3] including:

   • Severe obesity [4]

   • Marked RV dilation
   • Marked sternal abnormality
   • Hiatus hernia that distorts mediastinal anatomy
4. Patient has prior chest radiotherapy
5. Patient had previous mediastinitis
6. Patient had previous coronary artery bypass grafting procedure
7. Patient has existing transcatheter aortic valve replacement
8. Patient has gastrostomy tube
9. Patient has had a prior sternotomy, prior mediastinal instrumentation, prior abdominal surgery in the epigastric region, or planned sternotomy

10. Patient has previous pericarditis that:

    • Was chronic and recurrent, or

    • Resulted in pericardial effusion [5], or

    • Resulted in pericardial thickening or calcification [6]

11. Patients with a medical condition that precludes them from undergoing defibrillation testing, such as:

    • known LV thrombus

    • decompensated heart failure

    • LVEF <20% [7]
    • other physician discretion
12. Patient has persistent Atrial Fibrillation who is at high risk of a thromboembolic event with a CHA₂DS₂-VASc score ≥3, or is contraindicated for having anticoagulation interrupted for ≥72 hours

13. Patients with comorbidities which may increase surgical risk of complications[8] including:

    • severe aortic stenosis

    • COPD and is oxygen dependent
    • Hepatosplenomegaly
    • Marked hepatomegaly
14. Patient is on renal dialysis
15. Patient with any evidence of active infection or undergoing treatment for an infection
16. Patient with current implantation of neurostimulator or any other chronically implanted device which uses current in the body.
17. Patients with a limited life expectancy of less than 12 months
18. Patient is enrolled or planning to enroll in a concurrent drug or device study that may confound the results of this study, without documented pre-approval from a Medtronic study manager
19. Patient with any exclusion criteria as required by local law (e.g., age, pregnancy, breast feeding)
20. Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence [9]

[1] 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing).

[2] ACC/AHA/HRS guidelines for Cardiac Resynchronization Therapy [3] Per physician discretion [4] BMI > 40 [5] As documented on echo or MRI [6] As documented on CT scan or MRI [7] Most recent LVEF in the last 180 days (inclusive) [8] Per physician discretion [9] if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to EV ICD Pilot Study procedures

-

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental; Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.	Device: Defibrillation using the Extravascular ICD; VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Efficacy Outcome - Number of Participants That Had Successful Termination of Ventricular Fibrillation Episodes at Implantation	Each subject will demonstrate a successful defibrillation outcome if either 2 successive induced ventricular fibrillation episodes are terminated by the subject's device delivering a shock at the required energy level, or if one such episode is successfully terminated by the subject's device delivering a shock at a lower energy level. Up to 5 such episodes may be induced to test device efficacy.	At Implantation
Safety Outcome - Percentage of Participants With Freedom From Major System and Procedure Related Complications at 3 Months (90 Days)	Subjects will be monitored to determine whether they experience a major procedure- or system-related complication within 3 months (90 days) post-implant.	3 months (90 days)

Collaborators and Investigators

• Sponsor: Medtronic Cardiac Rhythm and Heart Failure
• Investigators: Principal Investigator: Ian G Crozier, MB ChB, Christchurch Hospital, Christchurch, New Zealand

Publications and helpful links

General Publications

• Crozier I, Haqqani H, Kotschet E, Shaw D, Prabhu A, Roubos N, Alison J, Melton I, Denman R, Lin T, Almeida A, Portway B, Sawchuk R, Thompson A, Sherfesee L, Liang S, Lentz L, DeGroot P, Cheng A, O'Donnell D. First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-Defibrillator. JACC Clin Electrophysiol. 2020 Nov;6(12):1525-1536. doi: 10.1016/j.jacep.2020.05.029. Epub 2020 Aug 26.

Study record dates

Study Major Dates

• Study Start (Actual): July 17, 2018
• Primary Completion (Actual): March 11, 2019
• Study Completion (Actual): November 15, 2023

Study Registration Dates

• First Submitted: June 12, 2018
• First Submitted That Met QC Criteria: July 24, 2018
• First Posted (Actual): August 1, 2018

Study Record Updates

• Last Update Posted (Actual): January 8, 2024
• Last Update Submitted That Met QC Criteria: January 3, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Tachycardia
• Other Study ID Numbers: MDT17034

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes